A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: the RibOB study
Ribociclib in combination with letrozole showed clear antitumor efficacy and safe treatment option in older patients with advanced breast cancer regardless of frailty. Frequent dose reductions and early discontinuation suggest the need for more research to optimize dosing in older patients.
Authors
- A. Laenen
- C. Kenis
- C. Quaghebeur
- A. Barbeaux
- P. Neven
- L. Decoster
- S. Hatse
- V. Verschaeve
- N.F. Ponde
- E. de Azambuja
- D.M.E.C. Verhoeven
- L. De Nys
- F. Cornelis
- M. Van Houdt
- J. Mebis
- H. Wildiers
Institutions
- Cliniques Universitaires Saint-Luc (BE)
- Université Libre de Bruxelles (BE)
- Universitair Ziekenhuis Leuven (BE)
- Institut Jules Bordet (BE)
- CHU Dinant Godinne UCL Namur (BE)
- AZ Klina (BE)
- Jessa Hospital (BE)
- Universitair Ziekenhuis Brussel (BE)
- CHR Verviers (BE)
- Grand Charleroi Hospital (BE)
- Daiichi Sankyo (United States) (US)
- KU Leuven (BE)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105896
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00